Tobramycin dry powder inhaler 28mg/capsule (TOBI)
- BNF:
- 5.1.4
- Status:
- Red
- Decision Date:
- April 2013
Comments
RED:1,2,3 NICE TA 276 treating pseudomonas lung infection in cystic fibrosis.
NHS England drug. To be used in line with NHS England commissioning intentions
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again